Conditions & Recovery · NCI News Releases · April 1, 2025

Combination immunotherapy shrank a variety of metastatic solid cancers

A new form of personalized cancer immunotherapy, known as tumor infiltrating lymphocyte (TIL) therapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers.

Originally published by NCI News Releases. We curate and add context; they did the reporting.

Read the full story at NCI News Releases ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor